Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Acquired by Millennium Management LLC

Millennium Management LLC raised its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 53.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,980,906 shares of the company's stock after acquiring an additional 1,043,228 shares during the period. Millennium Management LLC owned approximately 5.01% of Pyxis Oncology worth $4,650,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of PYXS. Ameriprise Financial Inc. bought a new position in Pyxis Oncology during the fourth quarter valued at $35,000. Caption Management LLC bought a new position in shares of Pyxis Oncology in the fourth quarter worth about $35,000. Commonwealth Equity Services LLC grew its holdings in shares of Pyxis Oncology by 61.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after purchasing an additional 10,000 shares during the last quarter. Graham Capital Management L.P. bought a new position in shares of Pyxis Oncology in the fourth quarter worth about $47,000. Finally, Bank of America Corp DE grew its holdings in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock worth $84,000 after purchasing an additional 9,062 shares during the last quarter. Institutional investors own 39.09% of the company's stock.

Pyxis Oncology Stock Up 0.8%

Shares of Pyxis Oncology stock traded up $0.01 during midday trading on Monday, hitting $1.22. The company had a trading volume of 559,923 shares, compared to its average volume of 741,267. The stock has a market cap of $75.58 million, a price-to-earnings ratio of -1.18 and a beta of 1.15. The company has a fifty day simple moving average of $1.07 and a 200 day simple moving average of $1.39. Pyxis Oncology, Inc. has a 12-month low of $0.83 and a 12-month high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, analysts expect that Pyxis Oncology, Inc. will post -1.04 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PYXS. Royal Bank of Canada restated an "outperform" rating and issued a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Pyxis Oncology in a report on Monday, May 19th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $9.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.